CytoDyn to Hold Conference Call Tuesday, May 26, to Provide Updates on Leronlimab for COVID-19 (Phase 2, 3, & eIND), Cancer (Metastatic Triple-Negative Breast Cancer, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD, and MS

CytoDyn Inc.(OTC.QB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, has announced that Nader Pourhassan, PhD, President and Chief Executive Officer, and Jacob Lalezari, MD, Chief Science Officer, will host an investment community conference call on Tuesday, May 26, 2020, to provide a comprehensive update on several recent clinical and regulatory developments. Management will dedicate approximately 30 minutes to address questions from analysts and investors. Date of the Conference Call: Tuesday, May 26, 2020, Time: 1:00 pm PDT / 4:00 pm EDT. Dial-In: 877-407-2986 US / 201-378-4916 International. A live audio webcast may also be accessed via CytoDyn’s corporate website at under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download, and install any necessary software. The webcast can also be accessed via the following link: A replay of the conference call will be available until June 26, 2020. To access the replay, interested parties may dial 877-660-6853 (US) / 201-612-7415 (international) and enter conference identification number 13702767. [CytoDyn press release] [CytoDyn]
Login Or Register To Read Full Story